TARRYTOWN, N.Y., Oct. 19, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced
"Our continued placement atop the Science Top Employers list is a reflection of our passionate colleagues who dedicate themselves each day to ground-breaking science that leads to life-changing medicines," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "Maintaining our culture of innovation and collaboration has been a key priority as we continue to grow beyond 6,000 people, explore new areas of research and help more patients."
The Science and Science Careers' 2017 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the best employers in these industries, as well as their driving characteristics. Survey respondents rated Regeneron highly based on 23 characteristics, including financial strength, easy adaptation to change and a research-driven environment. Employees rated Regeneron highest when it came to having a clear vision for the future, being socially responsible and treating colleagues with respect.
"Regeneron is proud to once again be recognized as the world's number one employer in our industry," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We also strive to be the best at bringing important new medicines to patients with unmet medical needs. That means having the best science, people and ethical standards, and creating an environment that rewards innovation and enables people to do their very best work."
According to Science, the 2017 global survey results were based on nearly 7,000 responses from North America (65 percent), Europe (25 percent) and the Asia/Pacific Rim (7 percent).
For the complete feature including individual company rankings, please visit www.sciencecareers.org/TopEmployers2017.
About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuiteŪ technologies, including VelocImmuneŪ to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Regeneron Media RelationsAlexandra BowieTel: +1 (914) [email protected]
View original content:http://www.prnewswire.com/news-releases/science-magazine-ranks-regeneron-1-biopharma-employer-for-fifth-time-300540067.html
SOURCE Regeneron Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All